NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,068 | -30.6% | 10,550 | -15.2% | 0.00% | -100.0% |
| Q1 2023 | $8,740 | -68.9% | 12,434 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $28,101 | -40.2% | 12,434 | 0.0% | 0.00% | -50.0% |
| Q2 2022 | $47,000 | -70.1% | 12,434 | -57.4% | 0.00% | -60.0% |
| Q1 2022 | $157,000 | -91.1% | 29,188 | -73.6% | 0.01% | -91.0% |
| Q4 2021 | $1,756,000 | +329.3% | 110,437 | +401.4% | 0.11% | +296.4% |
| Q3 2021 | $409,000 | +24.7% | 22,024 | +26.9% | 0.03% | +27.3% |
| Q2 2021 | $328,000 | +35.5% | 17,361 | +47.2% | 0.02% | +29.4% |
| Q1 2021 | $242,000 | -40.2% | 11,792 | +256.3% | 0.02% | -55.3% |
| Q2 2020 | $405,000 | -24.7% | 3,310 | -76.7% | 0.04% | -33.3% |
| Q4 2019 | $538,000 | +147.9% | 14,177 | +19.1% | 0.06% | +128.0% |
| Q3 2019 | $217,000 | – | 11,904 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |